Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...

And as an example of the Council’s commitment to advancing the field, they are currently collaborating in the RESILIENCE Trial, an EU-funded randomised controlled trial focused on exploring novel ...

The office of Senate Majority Leader Chuck Schumer (D-N.Y.) said that this week he will bring the HEARTS Act, the bipartisan ...

The devastating news of a cancer diagnosis understandably makes doctors and patients focus on the cancer itself. However, ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

CNS Pharmaceuticals ( (CNSP) ) has provided an announcement.

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...